Felip E, Altorki N, Zhou C, Vallieres E, et al. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. J Clin Oncol 2025 May 30:JCO2401681. doi: 10.1200/JCO-24-01681.
PMID: 40446184